| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $8,335,887 | 11 | 100 |
| Krasney Karen | EVP, GENERAL COUNSEL | 0 | $0 | 4 | $2.29M | $-2.29M |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER | 0 | $0 | 4 | $2.29M | $-2.29M |
| Sabar Karimah Es | director | 0 | $0 | 3 | $3.76M | $-3.76M |
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Over the last 12 months, insiders at Capricor Therapeutics, Inc. have bought $0 and sold $8.34M worth of Capricor Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Capricor Therapeutics, Inc. have bought $5.02M and sold $319.25M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,798,507 shares for transaction amount of $15M was made by Nippon Shinyaku Co Ltd (10 percent owner) on 2024‑09‑20.
| 2026-06-25 | Sale | Krasney Karen | EVP, GENERAL COUNSEL | 24,100 0.0527% | $30.38 | $732,158 | -68.45% | |
| 2026-06-25 | Sale | Bergmann Anthony | CHIEF FINANCIAL OFFICER | 24,100 0.0527% | $30.38 | $732,158 | -68.45% | |
| 2026-06-24 | Sale | Krasney Karen | EVP, GENERAL COUNSEL | 400 0.0009% | $30.00 | $12,000 | -66.99% | |
| 2026-06-24 | Sale | Bergmann Anthony | CHIEF FINANCIAL OFFICER | 400 0.0009% | $30.00 | $12,000 | -66.99% | |
| 2026-05-01 | Sale | Krasney Karen | EVP, GENERAL COUNSEL | 25,000 0.0561% | $31.70 | $792,548 | -27.73% | |
| 2026-05-01 | Sale | Bergmann Anthony | CHIEF FINANCIAL OFFICER | 25,000 0.0561% | $31.70 | $792,540 | -27.73% | |
| 2026-04-02 | Sale | Sabar Karimah Es | director | 7,529 0.0175% | $32.00 | $240,928 | -18.70% | |
| 2026-04-01 | Sale | Sabar Karimah Es | director | 53,735 0.1211% | $31.03 | $1.67M | -13.15% | |
| 2026-03-31 | Sale | Krasney Karen | EVP, GENERAL COUNSEL | 25,000 0.0542% | $30.12 | $752,935 | -13.49% | |
| 2026-03-31 | Sale | Bergmann Anthony | CHIEF FINANCIAL OFFICER | 25,000 0.0542% | $30.13 | $753,153 | -13.49% | |
| 2026-03-31 | Sale | Sabar Karimah Es | director | 61,265 0.133% | $30.17 | $1.85M | -13.49% | |
| 2024-09-20 | Nippon Shinyaku Co Ltd | 10 percent owner | 2.8M 9.1284% | $5.36 | $15M | +152.28% | ||
| 2023-10-12 | Musket David B | director | 410 0.0015% | $2.75 | $1,128 | +63.96% | ||
| 2023-10-10 | COLLIER EARL M JR | director | 10,000 0.0395% | $2.83 | $28,300 | +62.63% | ||
| 2023-10-09 | Musket David B | director | 5,083 0.02% | $2.82 | $14,334 | +66.01% | ||
| 2023-10-06 | Auwaerter Paul Gisbert | director | 5,000 0.019% | $2.84 | $14,200 | +58.45% | ||
| 2023-10-04 | Musket David B | director | 2,500 0.0095% | $2.90 | $7,250 | +61.62% | ||
| 2023-04-17 | Sale | Avat Xavier | 14,772 – | $64,258.00 | $949.22M | +3.61% | ||
| 2023-03-28 | Sale | Avat Xavier | 3,000 0.0118% | $4.06 | $12,180 | +6.46% | ||
| 2022-06-29 | Sale | Musket David B | 28,215 0.1163% | $3.77 | $106,371 | +19.68% |
| Krasney Karen | EVP, GENERAL COUNSEL | 30547 0.0531% | $287,141.80 | 2 | 4 | +25.52% |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER | 11223 0.0195% | $105,496.20 | 1 | 4 | +29.4% |
| Sabar Karimah Es | director | 0 0% | $0 | 0 | 3 | |
| Nippon Shinyaku Co Ltd | 10 percent owner | 7090351 12.3288% | $66.65M | 1 | 0 | +152.28% |
| CEDARS SINAI MEDICAL CENTER | 10 percent owner | 4049959 7.0421% | $38.07M | 4 | 0 | +25.52% |
| Marban Eduardo | 10 percent owner | 3173354 5.5179% | $29.83M | 2 | 0 | <0.0001% |
| KASH PETER M | director | 1596208 2.7755% | $15M | 3 | 0 | |
| TANEN DAVID M | director | 1520705 2.6442% | $14.29M | 4 | 0 | |
| GRASMICK LOUIS J | director | 1059740 1.8427% | $9.96M | 4 | 0 | +8.61% |
| St. John Edward A. | 10 percent owner | 842439 1.4648% | $7.92M | 2 | 0 | +25.52% |
| Marban Linda | Chief Executive Officer | 273709 0.4759% | $2.57M | 3 | 0 | +1.25% |
| Manzo Louis | director | 138384 0.2406% | $1.3M | 3 | 0 | +25.52% |
| BREWER RICHARD B | Executive Chairman | 125000 0.2174% | $1.18M | 1 | 0 | |
| Kazam Joshua A | director | 38084 0.0662% | $357,989.60 | 9 | 0 | +21.63% |
| Musket David B | director | 31536 0.0548% | $296,438.40 | 5 | 2 | +53.3% |
| COLLIER EARL M JR | director | 26856 0.0467% | $252,446.40 | 1 | 0 | +62.63% |
| Evans Daron | Chief Financial Officer | 25652 0.0446% | $241,128.80 | 7 | 0 | |
| Lieu Hsiao | Executive VP, Clinical Dev. | 12600 0.0219% | $118,440.00 | 2 | 0 | |
| Strumph Peter M | Chief Executive Officer | 7580 0.0132% | $71,252.00 | 3 | 0 | |
| Auwaerter Paul Gisbert | director | 5000 0.0087% | $47,000.00 | 1 | 0 | +58.45% |
| GERSHELL LELAND | CHIEF FINANCIAL OFFICER | 2100 0.0037% | $19,740.00 | 1 | 0 | +29.4% |
| SCHAFER GREGORY W | director | 100 0.0002% | $940.00 | 1 | 0 | |
| Avat Xavier | 0 0% | $0 | 1 | 1 | +19.68% |
$2,481,409 | 33 | 201.68% | $464.66M | |
Capricor Therapeutics, Inc. (CAPR) | $31,271,604 | 28 | 28.69% | $540.6M |
$112,238,340 | 19 | 39.16% | $514.11M | |
$2,516,932 | 19 | -15.78% | $461.19M | |
$133,809,976 | 13 | 31.29% | $605.85M | |
$6,385,840 | 12 | 0.69% | $627.73M | |
$130,748,265 | 10 | 53.98% | $613.63M | |
$6,847,110 | 9 | 5.96% | $495.68M | |
$62,616,785 | 8 | -7.00% | $580.23M | |
$13,043,783 | 8 | 732.82% | $565.8M | |
$5,529,561 | 8 | 5.30% | $522.59M | |
$17,675,244 | 7 | 92.20% | $486.09M | |
$21,792,890 | 6 | 75.72% | $558.08M | |
$164,999,952 | 5 | -44.44% | $547.08M | |
$4,745,999 | 5 | -4.91% | $591.84M | |
$209,740 | 4 | -1.93% | $466.56M | |
$2,720,023 | 3 | -11.76% | $609.97M | |
$20,020,000 | 1 | -75.24% | $501.56M | |
$3,850,000 | 1 | -51.32% | $462.17M |
| Increased Positions | 93 | +72.09% | 15M | +107.15% |
| Decreased Positions | 62 | -48.06% | 2M | -16.11% |
| New Positions | 49 | New | 9M | New |
| Sold Out Positions | 24 | Sold Out | 1M | Sold Out |
| Total Postitions | 160 | +24.03% | 27M | +91.05% |
| Blackrock, Inc. | $81,255.00 | 5.32% | 2.87M | -113,891 | -3.82% | 2025-09-30 |
| Vanguard Group Inc | $62,472.00 | 4.09% | 2.21M | -98,359 | -4.27% | 2025-09-30 |
| Geode Capital Management, Llc | $27,222.00 | 1.78% | 961,566 | -1,514 | -0.16% | 2025-09-30 |
| State Street Corp | $22,686.00 | 1.48% | 801,344 | -665,341 | -45.36% | 2025-09-30 |
| Morgan Stanley | $15,618.00 | 1.02% | 551,694 | +1,113 | +0.2% | 2025-09-30 |
| Pier Capital, Llc | $14,057.00 | 0.92% | 496,554 | +128,837 | +35.04% | 2025-09-30 |
| J. Goldman & Co Lp | $13,645.00 | 0.89% | 481,981 | +481,981 | New | 2025-09-30 |
| Dg Capital Management, Llc | $13,315.00 | 0.87% | 470,333 | +470,333 | New | 2025-09-30 |
| National Bank Of Canada /Fi/ | $11,259.00 | 0.74% | 397,700 | +229,000 | +135.74% | 2025-09-30 |
| Two Sigma Investments, Lp | $10,073.00 | 0.66% | 355,796 | +199,959 | +128.31% | 2025-09-30 |